The treatment drugs available aim to reduce symptoms and improve quality of life. These drugs help in easing the pain and discomfort caused due to leishmaniasis infection. The global Leishmaniasis Treatment Market is estimated to be valued at US$ 79.95 Bn in 2024 and is expected to exhibit a CAGR of 22.% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
Advancements in novel drug formulations specific for visceral and cutaneous forms of Global Leishmaniasis Treatment Market Size are expected to drive market growth over the forecast period. Major market players are focusing on development of less toxic and more effective treatment drugs. For instance, in June 2021, Sarepta Therapeutics, Inc. announced positive top-line data from Part A of an ongoing Phase 1/2 study evaluating the safety, tolerability and pharmacokinetics of its investigational gene therapy, SRP-9001, for the treatment of Leishmaniasis. This development of targeted drug is anticipated to boost market growth during the forecast period.
Segment Analysis
The global leishmaniasis treatment market is dominated by the systemic treatment sub-segment owing to its effectiveness in completely curing the disease. Systemic treatments are prescribed for severe and visceral forms of leishmaniasis and involve the administration of medications throughout the body either orally or through injection. They show better results against leishmania parasites located deep inside tissues or organs.
Key Takeaways:
The global leishmaniasis treatment market is expected to witness high growth over the forecast period of 2024-2031.
Regional analysis: North America region currently dominates the market and is expected to maintain its position during the forecast period. This is attributed to growing research funding and increasing awareness regarding leishmaniasis treatment in the region. However, the Asia Pacific region is anticipated to showcase the fastest growth rate owing to rising incidence of leishmaniasis cases and growing healthcare expenditure in developing countries such as India and China.
Key players: Key players operating in the leishmaniasis treatment market are Johnson & Johnson, Intrabio, Cyclo Therapeutics, Inc., Kempharm, Inc., Azafaros B.V., Sarepta Therapeutics, Inc. These players are focusing on new drug development and licensing & collaboration activities to strengthen their product portfolios and market positions. For instance, in February 2021, Intrabio signed an agreement with the Drugs for Neglected Diseases initiative (DNDi) to develop novel treatments for leishmaniasis.
Get More Insights On This Topic: https://www.ukwebwire.com/leishmaniasis-treatment-market-size-share-analysis-2023-2030/
Explore More Trending Article On This Topic: https://captionssky.com/bridging-nature-and-innovation-unravelling-the-wonders-of-synthetic-biologys-genetic-tapestry/
Comments
0 comment